Cited by 4,319Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesRenal cell carcinoma treatment

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Open access

Reig, Maria, Forner, Alejandro, Rimola, Jordi, Ferrer-Fàbrega, Joana, Burrel, Marta, Garcia-Criado, Ángeles, Kelley, Robin K., Galle, Peter R., Mazzaferro, Vincenzo, Salem, Riad, Sangro, Bruno, Singal, Amit G., Vogel, Arndt, Fuster, Josep, Ayuso, Carmen, Bruix, Jordi·2022·Journal of Hepatology

DOI 10.1016/j.jhep.2021.11.018PMC PMC8866082

Open this paper in CoChat — free account Open PDF

Abstract

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.11.018

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citation
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citation
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Self-citation
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Hepatocellular carcinoma
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,774
Self-citation
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586

Show all 136 references

Sorted by citations

Items 701–800 of 1,000

Treatment for hepatocellular carcinoma after immunotherapy
Chan, L. L., Kwong, T. T., Yau, J., & Chan, S. L. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101781 · Cited by 16
“These agents have been approved in the ﬁ rst-line setting due to their established ef ﬁ cacy and safety, the rationale of offering an alternative mechanism of action, and their accessibility, despite the lack of high-quality data to guide management in this context [18 − 20].”
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study
Nault, J., Boubaya, M., Wartski, M., Dohan, A. J. J., Pol, S., Pop, G., Soussan, M., Sutter, O., Costentin, C. E., Roux, J., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00011-1 · Cited by 14
Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases
Burra, P., Cammà, C., Invernizzi, P., Marra, F., & Pompili, M. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101900 · Cited by 17
Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system
Meng, C., Zhang, H., Yi, X., Kong, G., Zhang, X., Wang, B., Xu, Y., Qi, H., Wu, Q., Zhang, K. K., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02480-x · Cited by 15
Prospective analysis on the outcomes of histotripsy for primary and metastatic liver tumors
Chan, A. C. Y., Lau, V., Wong, G. T. C., Chan, Y., Man, K., Ng, L. Y., Ma, H., Husain, A., & Ng, I. O. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003856 · Cited by 14
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?
Fulgenzi, C. A. M., D’Alessio, A., Ogunbiyi, O., Demirtaş, C. Ö., Gennari, A., Cortellini, A., Sharma, R., & Pinato, D. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2072726 · Cited by 14
Multitargeting Strategy Using Tetrathiomolybdate and Lenvatinib: Maximizing Antiangiogenesis Activity in a Preclinical Liver Cancer Model
Li, N., Yonghui, H., Wan, Y., & Guodong, C. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220907115027 · Cited by 14
Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation
Dennis, C. V., Prince, D. S., Moayed-Alaei, L., Remash, D., Carr‐Boyd, E., Bowen, D. G., Strasser, S. I., Crawford, M. W., Pulitanò, C., Kench, J. G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.997093 · Cited by 14
Immunogenic change after percutaneous microwave ablation in pulmonary malignancies: Variation in immune cell subsets and cytokines in peripheral blood
Zhang, L., Zhang, M., Wang, J., Li, Y., Wang, T., Xia, J., Feng, B., & Shen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1069192 · Cited by 14
Prolonged Survival after Recurrence in HCC Resected Patients Using Repeated Curative Therapies: Never Give Up!
Toubert, C., Guiu, B., Taweel, B. A., Assénat, E., Panaro, F., Souche, F.-R., Bedoya, J. U., Navarro, F., & Herrero, A. (2022) · Cancers · doi:10.3390/cancers15010232 · Cited by 14
“The choice of treatment for recurrence was discussed in a multidisciplinary consultation meeting, according to the BCLC algorithm for the management of HCC [6].”
Method
The role of platelet-lymphocyte ratio in hepatocellular carcinoma: a valuable prognostic marker
Chan, K. S., & Shelat, V. G. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-2343 · Cited by 14
Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Yamauchi, R., Ito, T., Yoshio, S., Yamamoto, T., Mizuno, K., Ishigami, M., Kawashima, H., Yasuda, S., Shimose, S., Iwamoto, H., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01985-w · Cited by 14
“The results of these trials led to the approval of the Atez/Bev regimen, which is currently the first-line treatment for advanced uHCC [8].”
Result
Outcomes of National Survey of the Practice of Hepatocellular Carcinoma Surveillance
Scott, R. A., Cross, T., Clarke, C. G. D., Khan, S. A., Ryder, S. D., Franklin, J. M., & Aravinthan, A. D. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s403702 · Cited by 14
“Furthermore, survival of patients with early-stage HCC is significantly higher, at least in part due to the availability of curative treatment options, compared to those with intermediate and advanced-stage HCC.(5)”
Influential
Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
Nevola, R., Femine, A. D., Rosato, V., Kondili, L. A., Alfano, M., Mastrocinque, D., Imbriani, S., Perillo, P., Beccia, D., Villani, A., et al. (2023) · Cancers · doi:10.3390/cancers15112950 · Cited by 14
Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study
Moon, A. M., Kim, H. P., Singal, A. G., Owen, D., Mendiratta‐Lala, M., Parikh, N. D., Rose, S. C., McGinty, K., Agala, C. B., Burke, L. M. B., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000184 · Cited by 14
“Performance status may be underestimated in patients with HCC, given the effects of cirrhosis on activities of daily living,[5] and this may have contributed to the high proportion of patients with ECOG ≥ 1 patients who were considered BCLC-C HCC despite a low burden of intrahepatic disease.”
BackgroundMethodInfluentialSelf-citation
Noninvasive imaging-based machine learning algorithm to identify progressive disease in advanced hepatocellular carcinoma receiving second-line systemic therapy
Dong, W., Ji, Y., Pi, S., & Chen, Q.-F. (2023) · Scientific Reports · doi:10.1038/s41598-023-37862-y · Cited by 12
Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
Motomura, K., Kuwano, A., Tanaka, K., Koga, Y., Masumoto, A., & Yada, M. (2023) · Cancers · doi:10.3390/cancers15174345 · Cited by 14
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
Tanaka, K., Tsuji, K., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2023) · Cancers · doi:10.3390/cancers15174348 · Cited by 14
“The newest BCLC strategy [39] recommends the introduction of systemic treatment prior to TACE in TACE-unsuitable BCLC-B patients.”
Method
Development and Validation of a Propionate Metabolism-Related Gene Signature for Prognostic Prediction of Hepatocellular Carcinoma
Xiao, J., Wang, J., Zhou, C., & Luo, J. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s420614 · Cited by 14
“In current practice, it is widely used to predict the prognosis of HCC using the Barcelona Clinic Liver Cancer (BCLC) classification.(3) However, some patients with similar tumor stages exhibit different outcomes, suggesting that the staging system is still lacking.”
The Current Evidence of Intensity-Modulated Radiotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Jang, W. I., Jo, S., Moon, J. E., Bae, S. H., & Park, H. C. (2023) · Cancers · doi:10.3390/cancers15204914 · Cited by 14
“The BCLC 2022 guidelines recommend a combination therapy of immunotherapy and bevacizumab as the ﬁrst regimen for BCLC stages B and C [72].”
Method
Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M
Heo, S., Kang, H. J., Choi, S. H., Kim, S., Yoo, Y., Choi, W., Kim, S. Y., & Lee, S. S. (2023) · European Radiology · doi:10.1007/s00330-023-10305-y · Cited by 14
Role of Immunological Cells in Hepatocellular Carcinoma Disease and Associated Pathways
Aasarey, R., Yadav, K., Kashyap, B. K., Prabha, S., Kumar, P., Kumar, A., Ruokolainen, J., & Kesari, K. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00216 · Cited by 14
Questionnaire survey of Japanese board‐certified expert hepatobiliary and pancreatic surgeons and instructors on the surgical indications for hepatocellular carcinoma
Akahoshi, K., Shindoh, J., Tanabe, M., Watanabe, S., Takamizawa, H., Eguchi, S., Endo, I., Kubo, S., Taketomi, A., Nagano, H., et al. (2023) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1408 · Cited by 14
“15 However, there remains no consensus on the current position of surgery in the multidisciplinary treatment of advanced HCC.”
Background
Immunotherapy before liver transplant in unresectable hepatocellular carcinoma: a case report
Ohm, H., Khwaja, R., & Karachiwala, H. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-634 · Cited by 14
Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate
Chen, Q., Chen, S., Chen, M., Lyu, N., & Zhao, M. D. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00403 · Cited by 14
Immune Effects of Intra-Arterial Liver-Directed Therapies
Karimi, A., Yarmohammadi, H., & Erinjeri, J. P. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.10.019 · Cited by 14
The role of cold ischemia time and hypothermic perfusion in predicting early hepatocellular carcinoma recurrences after liver transplantation
Dajti, G., Germinario, G., Prosperi, E., Siniscalchi, A., Vasuri, F., Valente, S., Odaldi, F., Maroni, L., Serenari, M., Bertuzzo, V. R., et al. (2024) · Artificial Organs · doi:10.1111/aor.14715 · Cited by 14
Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using CT radiomics-based machine learning model
Zhang, X., He, Z., Zhang, Y., & Kong, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1315732 · Cited by 14
Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning
Liu, W., Wei, R., Chen, J., Li, Y., Pang, H., Zhang, W., An, C., & Li, C. (2024) · European Radiology · doi:10.1007/s00330-024-10581-2 · Cited by 15
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody
Wang, L., Feng, J.-K., Lu, C., Wu, J., Zhou, B., Wang, K., Wei, X., Liang, C., Zhou, H., Shi, J., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae032 · Cited by 14
Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice
de Mattos, Â. Z., Bombassaro, I., Vogel, A., & Debes, J. D. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i19.2488 · Cited by 15
Self-citation
Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA): A Comparative Analysis
Wijnen, N., Bruijnen, R. C. G., Vonken, E.-J. P. A., de Jong, H. W. A. M., de Bruijne, J., Bol, G. M., Hagendoorn, J., Intven, M., & Smits, M. L. J. (2024) · Cancers · doi:10.3390/cancers16101925 · Cited by 14
“Due to the minimally invasive nature of image-guided thermal ablation and outcomes comparable to surgical resection, it has become a treatment of choice in several guidelines [5,6].”
Background
Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience
Zhao, W., Liu, C., Wu, Y., Yao, Z., Dou, Q., Li, W., Zhao, X., & Xia, N.-X. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-93 · Cited by 14
TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
Tang, Z., Bai, T., Wei, T., Wang, X., Chen, J., Ye, J., Li, S., Wei, M., Li, X., Lin, Y., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12484-3 · Cited by 14
“According to BCLC strategy for prognosis prediction and treatment recommendation (the 2022 update) [4], TACE is recommended as the primary treatment for BCLC-B stage HCC that exceeds the Milan criteria.”
Method
Machine learning models including preoperative and postoperative albumin-bilirubin score: short-term outcomes among patients with hepatocellular carcinoma
Endo, Y., Tsilimigras, D. I., Munir, M. M., Woldesenbet, S., Guglielmi, A., Ratti, F., Marques, H. P., Cauchy, F., Lam, V. W. T., Poultsides, G. A., et al. (2024) · HPB · doi:10.1016/j.hpb.2024.07.415 · Cited by 14
Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study
Iseda, N., Itoh, S., Toshima, T., Yoshiya, S., Bekki, Y., Tsutsui, Y., Toshida, K., Inokuchi, S., Utsunomiya, T., Tomino, T., et al. (2024) · Surgery Today · doi:10.1007/s00595-024-02930-x · Cited by 14
“The Barcelona Clinic Liver Cancer staging system recommends that systemic treatment, such as that with a molecular-targeted agent, should be considered as the first approach for such cases [8].”
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆
Xia, D., Bai, W., Wang, Q., Chung, J. W., Adhoute, X., Kloeckner, R., Zhang, H., Zeng, Y., Sripongpun, P., Nie, C., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101216 · Cited by 14
Self-citation
Transarterial Radioembolization Can Downstage Intermediate and Advanced Hepatocellular Carcinoma to Liver Transplantation
Berardi, G., Guglielmo, N., Cucchetti, A., Usai, S., Colasanti, M., Meniconi, R. L., Ferretti, S., Mariano, G., Angrisani, M., Sciuto, R., et al. (2024) · Transplantation · doi:10.1097/tp.0000000000005204 · Cited by 14
Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy
Malone, C. D., Bajaj, S., He, A., Mody, K., Hickey, R., Sarwar, A., Krishnan, S., Patel, T. C., & Toskich, B. B. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.11.012 · Cited by 15
Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the Prospective Multicenter Observational HepaStar Trial
Collettini, F., Andrašina, T., Reimer, P., Schima, W., Stroszczynski, C., Lamprecht, Y., Auer, T. A., Rohan, T., Wildgruber, M., Gebauer, B., et al. (2024) · European Radiology · doi:10.1007/s00330-024-11272-8 · Cited by 14
PD1+ Treg cell remodeling promotes immune homeostasis within peripheral blood and tumor microenvironment after microparticles-transarterial chemoembolization in hepatocellular carcinoma
Ren, Z., Wang, Y., Jiang, D., Liu, Y., Yang, X., Wang, T., Zhu, J., Wang, W., Chen, Q., & Zhang, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03962-z · Cited by 14
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma
Lim, M., Espinoza, M., Huang, Y., Franses, J. W., Zhu, H., & Hsiehchen, D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.61735 · Cited by 14
Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/β-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma
Hamaguchi, K., Miyanishi, K., Osuga, T., Tanaka, S., Ito, R., Sakamoto, H., Kubo, T., Ohnuma, H., Murase, K., Takada, K., et al. (2022) · Cancers · doi:10.3390/cancers14092066 · Cited by 14
Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh Class A Liver function: A Pilot Study
Wang, F., Numata, K., Komiyama, S., Miwa, H., Sugimori, K., Ogushi, K., Moriya, S., Nozaki, A., Chuma, M., Ruan, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.843680 · Cited by 14
Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines
Goyal, P., Salem, R., & Mouli, S. K. (2022) · British Journal of Radiology · doi:10.1259/bjr.20220379 · Cited by 15
Self-citation
Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma
Oikawa, T., Yamada, K., Tsubota, A., Saeki, C., Tago, N., Nakagawa, C., Ueda, K., Kamioka, H., Taniai, T., Haruki, K., et al. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.07.020 · Cited by 14
Early experiences with developing techniques for pure laparoscopic explant hepatectomy in living donor liver transplantation
Kim, J. C., Hong, S. K., Lee, K., Lee, S., Suh, S., Hong, S. Y., Han, E. S., Choi, Y., Yi, N., & Suh, K. (2022) · Liver Transplantation · doi:10.1002/lt.26564 · Cited by 14
Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients
Jung, W. J., Jang, S., Choi, W. J., Park, J., Choi, G. H., Jang, E. S., Jeong, S., Choi, W. S., Lee, J. H., Yoon, C. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18341-2 · Cited by 14
Highlighting novel targets in immunotherapy for liver cancer
Ruff, S. M., Shannon, A. H., Beane, J. D., & Pawlik, T. M. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2150841 · Cited by 14
The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization
Sun, B., Zhang, L., Xiang, D., Li, Q., Ren, Y., Cao, Y., Sun, T., Zhang, W., Wu, L., Zhu, L., et al. (2022) · Journal of Oncology · doi:10.1155/2022/7062105 · Cited by 14
“For such patients, TACE, tyrosine kinase inhibitors (TKI), or TKI combined with immunotherapy are recommended as the frst-line treatments [11, 13].”
Background
Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
Leal, C. R. G., de Matos, J. P. S., Theodoro, C. F., Teixeira, R., Perez, R. D. M., Guaraná, T., Pinto, P. D. T. A., Guimarães, T., & de Oliveira, S. A. (2023) · Viruses · doi:10.3390/v15010221 · Cited by 14
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Liu, J., Li, J.-J., Yan, S., Zhang, G.-N., & Yi, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1074793 · Cited by 14
Annals of Surgical Oncology Practice Guidelines Series: Management of Primary Liver and Biliary Tract Cancers
Ruff, S. M., Cloyd, J. M., & Pawlik, T. M. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14255-z · Cited by 16
“1,3,9,11 Careful attention to the FLR quality and volume is necessary.”
Background
Final Results of a Multicenter Prospective Study of Stereotactic Body Radiation Therapy for Previously Untreated Solitary Primary Hepatocellular Carcinoma (The STRSPH Study)
Sanuki, N., Kimura, T., Takeda, A., Ariyoshi, K., Oyamada, S., Yamaguchi, T., Tsurugai, Y., Doi, Y., Kokubo, M., Imagumbai, T., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.10.040 · Cited by 13
The Emerging Role of Histotripsy in Liver Cancer Treatment: A Scoping Review
Queen, H., Ferris, S. F., Cho, C. S., & Ganguly, A. (2025) · Cancers · doi:10.3390/cancers17060915 · Cited by 13
“Another recent guideline for the staging and management of HCC is the Barcelona Clinic Live Cancer (BCLC) prognosis and treatment strategy [19].”
Harnessing Plasma Biomarkers to Predict Immunotherapy Outcomes in Hepatocellular Carcinoma: The Role of cfDNA, ctDNA, and Cytokines
Vargas‐Accarino, E., Higuera, M., Bermúdez-Ramos, M., Soriano-Varela, A., Torrens, M., Pons, M., Aransay, A. M., Martín, J., Rodríguez‐Frias, F., Merino, X., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062794 · Cited by 13
“However, three months after initiating treatment, patients who did not survive exhibited significantly higher AFP levels (157.5 [8.7, 7875] vs. 3.9 [2, 7.2], p = 0.008).”
Influential
Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective
Lee, I. J., & Kim, H. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2025.0308 · Cited by 13
“TARE is recommended as an alternative treatment for early stage HCC in the Barcelona Clinic Liver Cancer (BCLC) staging system [1] and for single or localized tumors in the Korean Liver Cancer Association National Cancer Center (KLCA-NCC) guidelines [2-4].”
Ferroptosis and the cGAS–STING pathway into precision nano-immuno-theranostics: A mechanistic paradigm for reversing drug resistance in hepatocellular carcinoma
Elmetwalli, A. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101326 · Cited by 16
The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience
HIDAKA, M., Hara, T., Soyama, A., Sasaki, R., Matsushima, H., Tanaka, T., Hamada, T., Imamura, H., Adachi, T., Kanetaka, K., et al. (2022) · Anticancer Research · doi:10.21873/anticanres.15791 · Cited by 13
Current trends in regenerative liver surgery: Novel clinical strategies and experimental approaches
Heil, J., Schiesser, M., & Schadde, E. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.903825 · Cited by 13
Data-Driven Assisted Decision Making for Surgical Procedure of Hepatocellular Carcinoma Resection and Prognostic Prediction: Development and Validation of Machine Learning Models
Wang, L., Song, D., Wang, W., Li, C., Zhou, Y., Zheng, J., Rao, S., Wang, X., Shao, G., Cai, J., et al. (2023) · Cancers · doi:10.3390/cancers15061784 · Cited by 13
“Hepatectomy is currently one of the most effective curative treatments [4], while the long-term oncological outcome is still poor due to high recurrence rates and metastasis after surgery [5].”
Background
Role of sirtuins in hepatocellular carcinoma progression and multidrug resistance: Mechanistical and pharmacological perspectives
Ceballos, M. P., Quiroga, A. D., & Palma, N. F. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115573 · Cited by 14
Bridging locoregional treatment prior to liver transplantation for cirrhotic patients with hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis
Kostakis, I. D. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0812 · Cited by 13
Immunotherapy and Liver Transplantation
Tabrizian, P., Yu, A. T., Debnath, N., Myers, B., & Marron, T. U. (2023) · Surgical Clinics of North America · doi:10.1016/j.suc.2023.07.009 · Cited by 13
Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma
Hu, Y., Pan, T., Cai, X., He, Q.-S., Zheng, Y., Huang, M., Jiang, Z., Chen, J., & Wu, C. T. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-486 · Cited by 13
Tissue Circular RNA_0004018 and 0003570 as Novel Prognostic Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma
Kang, M. K., Kim, G., Park, J. G., Jang, S. Y., Lee, H. W., Tak, W. Y., Kweon, Y. O., Park, S. Y., Lee, Y. R., & Hur, K. (2023) · Genes · doi:10.3390/genes14101963 · Cited by 13
“The Modiﬁed Union for International Cancer Control and Barcelona Clinic Liver Cancer (BCLC) classiﬁcation was used for HCC staging [2,15].”
Method
Laparoscopic versus open liver resection for multiple hepatocellular carcinoma within and beyond the Milan criteria: An Eastern‐Western propensity score–matched analysis
Cassese, G., Han, H., Lee, E., Lee, B., Lee, H. W., Cho, J. Y., Montalti, R., & TROISI, R. I. (2023) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1384 · Cited by 13
“7 Nonetheless, it has been widely re-ported that referral HPB centers perform LR in selected HCC patients also for BCLC-B and BCLC-C patients, as well as for patients with multiple HCC. 8,9 Indeed, some trials have indicated that liver resection may offer better oncological outcomes than TA or TACE.”
Background
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison
Agirrezabal, I., Bouattour, M., Pinato, D. J., D’Alessio, A., Brennan, V. K., Carion, P. L., Shergill, S., Amoury, N., & Vilgrain, V. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113427 · Cited by 13
Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients
Lin, K., Chen, Q.-J., Tang, S.-C., Lin, Z.-W., Zhang, J., Zheng, S.-M., Li, Y.-T., Wang, X., Lu, Q., Fu, J., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11693-6 · Cited by 13
“The prognosis of HCC depends significantly on the staging of the disease and suitable treatment options [8, 9].”
BackgroundMethodInfluential
New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma
Dalzell, C. G., Taylor, A. C., & White, S. B. (2023) · Cancers · doi:10.3390/cancers15245749 · Cited by 14
From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies
Chen, L., He, Z., Tao, Q., Tang, X., Jiang, L., Tu, X., Liu, Z., Chen, H., Xie, F., & Zheng, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247665 · Cited by 13
“…of the BCLC strategy, which recommends radical ablation, resection and transplantation for patients with stage 0 and stage A(Single, or 2–3 nodules each ≤ 3 cm), and transplantation for selected patients with stage B (multinodular) who meet the expanded criteria for liver transplantation [4].”
Background
Proposal for Prognosis-Oriented Definition of Borderline Resectable Hepatocellular Carcinoma
Haruki, K., Harimoto, N., Furukawa, K., Taniai, T., Yanagaki, M., Igarashi, Y., Tsunematsu, M., Shirai, Y., Shirabe, K., & Ikegami, T. (2024) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000001032 · Cited by 13
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma
Garcia-Reyes, K., Gottlieb, R. A., Menon, K. M., Bishay, V. L., Patel, R., Patel, R., Nowakowski, S. F., Sung, M. W., Marron, T. U., Gansa, W. H., et al. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.02.004 · Cited by 13
Thermal ablation for hepatic tumors in high-risk locations
Ndhlovu, E., Zhang, B., Chen, X., & Zhu, P. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102300 · Cited by 13
Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma
Yang, J., Shang, X., Li, J., & Wei, N. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-821 · Cited by 13
Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy
Gao, Y., Gong, Y., Lu, J., Hao, H., & Shi, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1377722 · Cited by 13
“No longer eligible for curative or locoregional therapies, these patients with advanced liver tumor can only choose to seek systemic treatment (10).”
Background
Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
Ma, K.-P., Fu, J., Duan, F., & Wang, M. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i4.1236 · Cited by 13
“Transarterial chemoembolization (TACE) is the standard locoregional therapy considered in such cases[2].”
Current Trends and Advancements in the Management of Hepatocellular Carcinoma
Teufel, A., Kudo, M., Qian, Y., Daza, J., Rodriguez, I., Reissfelder, C., Ridruejo, E., & Ebert, M. P. (2024) · Digestive Diseases · doi:10.1159/000538815 · Cited by 14
Interpretable machine learning based on CT-derived extracellular volume fraction to predict pathological grading of hepatocellular carcinoma
Li, J., Zou, L., Ma, H., Zhao, J., Wang, C., Li, J., Hu, G., Yang, H., Wang, B., Xu, D., et al. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04313-9 · Cited by 15
“In general, the BCLC stage system is commonly used to assess the progression and prognosis of HCC [39].”
Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis
Schindler, P., Kaldewey, D., Rennebaum, F., Trebicka, J., Pascher, A., Wildgruber, M., Köhler, M., & Masthoff, M. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05722-5 · Cited by 13
“This minimally invasive locoregional endovascular therapy combines the dual effects of delivering chemotherapeutic agents directly to the tumor site while inducing ischemic necrosis through embolic agents, making it a cornerstone in the treatment algorithm for HCC (Reig et al. 2022).”
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
Zhang, Y., Zhang, H., Xu, H., Wang, Y., Feng, L., & Yi, F. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03396-4 · Cited by 13
“%) of targeted therapy and immunotherapy has the best efficacy [35].”
Background
Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel
Thornton, L. M., Abi‐Jaoudeh, N., Lim, H. J., Malagari, K. S., Spieler, B. O., Kudo, M., Finn, R. S., Lencioni, R. A., White, S. B., Kokabi, N., et al. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.02.017 · Cited by 13
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
Werner, W., Kuzminskaya, M., Lurje, I., Tacke, F., & Hammerich, L. (2024) · Seminars in Liver Disease · doi:10.1055/a-2334-8311 · Cited by 14
Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma
Bajestani, N., Wu, G., Hussein, A. E., & Makary, M. S. (2024) · Biomedicines · doi:10.3390/biomedicines12071432 · Cited by 13
“…characterized by diffuse, infiltrative bilobar involvement and those in advanced stages (BCLC C and D) who exhibit extrahepatic invasion or end-stage liver function and are not eligible for curative treatments due to the advanced nature of their disease or the presence of comorbid conditions [4].”
Background
Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
Stefano, N. D., Patrono, D., Colli, F., Rizza, G., Paraluppi, G., & Romagnoli, R. (2024) · Cancers · doi:10.3390/cancers16132374 · Cited by 13
“Another significant advancement in HCC treatment, as emphasized by the BCLC guidelines, pertains to systemic therapy [5].”
Influential
Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial
Hao, Y., Xie, F., Zhou, Y., Li, C., Zhang, X., Shen, J., Yao, M., Sun, X., Zhou, J. J., Wen, T., et al. (2024) · Trials · doi:10.1186/s13063-024-08340-1 · Cited by 13
“In contrast, the BCLC staging system suggests that single large HCCs often present with tumor-related symptoms, and HCC with symptoms should be staged as advanced disease [4].”
Background
Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study
Fu, Y., Yang, Z., Liu, S., Guan, R., Wang, X., Chen, J., Wang, J., Pan, Y., Liu, M., Chen, M., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001977 · Cited by 13
Liver Resection for Hepatocellular Carcinoma: Recent Advances
Gundavda, K. K., Patkar, S., Varty, G. P., Shah, N., Velmurugan, K., & Goel, M. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102401 · Cited by 17
Prognostic role of albumin-bilirubin (ALBI) score and Child-Pugh classification in patients with advanced hepatocellular carcinoma under systemic treatment
da Fonseca, L. G., de Melo, M. A. Z., da Silveira, T. H. M., Yamamoto, V. J., Hashizume, P. H. S., & Sabbaga, J. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1748 · Cited by 13
Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta‐analysis
Komiyama, S., Takeda, A., Tateishi, Y., Tsurugai, Y., Eriguchi, T., & Horita, N. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110614 · Cited by 13
Demographics and Immunotherapy Efficacy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Phase III Clinical Trials
Shao, Y., & Akhmetzhanov, A. R. (2024) · Liver Cancer · doi:10.1159/000542576 · Cited by 15
Prediction of therapeutic response to transarterial chemoembolization plus systemic therapy regimen in hepatocellular carcinoma using pretreatment contrast-enhanced MRI based habitat analysis and Crossformer model
Zhu, Y., Liu, T., Chen, J., Wen, L., Zhang, J., & Zheng, D. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04709-7 · Cited by 13
“Meanwhile, systemic therapy, which consists of immunotherapies and molecular targeted therapies (MTT), constitutes the standard approach in a first-line clinical set - ting [6 ].”
The assessment of impaired liver function and prognosis in hepatocellular carcinoma
Pantea, R., Bednarsch, J., Schmitz, S. M., Meister, P., Heise, D., Ulmer, T. F., Neumann, U. P., & Lang, S. A. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2442573 · Cited by 14
“Hence, this concept has been included into BCLC guidelines, now allowing LT as treatment option even among individuals initially staged BCLC B [10].”
Influential
Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
Park, K., Lee, H. W., Kim, E., Choi, W., Lee, D., Shim, J. H., Kim, K. M., Lim, Y., Lee, H. C., Yoo, C., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18526 · Cited by 13
Hepatocellular Carcinoma Screening: From Current Standard of Care to Future Directions
Mohnasky, M., Gad, S., Moon, A. M., Barritt, A. S., Charalel, R. A., Eckblad, C., Caddell, A., Xing, M., & Kokabi, N. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2024.10.014 · Cited by 15
Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide
Nagalapuram, V., Popuri, N., Nipp, R. D., Ulahannan, S. V., & Lau‐Min, K. S. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00872 · Cited by 14
Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
Wang, Y., Pan, S., Tian, J., Wang, J., Yu, Y., Wang, S., Li, F., Yang, L., Liu, X., Shen, Y., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04038-8 · Cited by 13
Immunotherapy and Transarterial therapy of HCC : What the interventional radiologist needs to know about the changing landscape of HCC treatment?
Tibballs, J. M., & Clements, W. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13405 · Cited by 13
Surgical Resection of a Recurrent Hepatocellular Carcinoma with Portal Vein Thrombosis: Is It a Good Treatment Option? A Case Report and Systematic Review of the Literature
Sena, G., Paglione, D., Gallo, G., Goglia, M., Osso, M., & Nardo, B. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185287 · Cited by 13
Modified Albumin–Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy
Hsu, W., Hsu, S.-C., Chen, T.-H., Lin, C., Lin, Y., Chang, Y., Wang, H., Liao, Y.-M., Lai, H., & Peng, C. (2022) · Cancers · doi:10.3390/cancers14205083 · Cited by 13

Authors: Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J.
Affiliations: Hospital Clínic de Barcelona (ES)
University of California, San Francisco (US)
University Medical Center of the Johannes Gutenberg University Mainz (DE)
University of Milan (IT)
Northwestern University (US)
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
The University of Texas Southwestern Medical Center (US)
Medizinische Hochschule Hannover (DE)
Corresponding author: Bruix, Jordi
ORCID: Reig, Maria
Forner, Alejandro
Rimola, Jordi
Burrel, Marta
Garcia-Criado, Ángeles
Kelley, Robin K.
Galle, Peter R.
Mazzaferro, Vincenzo
Salem, Riad
Sangro, Bruno
Singal, Amit G.
Vogel, Arndt
Fuster, Josep
Ayuso, Carmen
Bruix, Jordi
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2022-03
Volume: 76
Issue: 3
Pages: 681-693
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2021.11.018
PMC: PMC8866082
OpenAlex: W3213277274
Cited by: 4,319
References: 136
Citations by year: 2026: 684 · 2025: 1071 · 2024: 1166 · 2023: 962 · 2022: 424
FWCI: 83.72
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
eScholarship (California Digital Library) (submittedVersion)
Funders: Fundación Científica de la Asociación Española Contra el Cáncer (PI044031)
National Institutes of Health (R01 R01 MD012565, PI18/00768)
Horizon 2020 Framework Programme (952103)
Instituto de Salud Carlos III (AC16/00065, PI18/0358, PI15/00145, PI18/00542, PI19/00742, PI18/00768)
European Association for the Study of the Liver
Horizon 2020
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: hepatocellular carcinoma, Barcelona Clinic Liver Cancer staging, outcome prediction, treatment guidelines, evidence-based clinical decision-making
MeSH terms: Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Severity of Illness Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks